Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05362097
Other study ID # GuangzhouIRD-LSUN3
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 5, 2023
Est. completion date May 5, 2026

Study information

Verified date March 2023
Source Guangzhou Institute of Respiratory Disease
Contact lihong Sun, doctor
Phone 02083062284
Email sunlihong@126.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

At present, there is no research scale designed for the quality of life of children with chronic cough in China, most of them use the cough scale designed for adults to evaluate the quality of life of children. In China, more and more attention has been paid to evaluate and improve the quality of life of children with chronic cough, but cough specific quality of life measurement tools for adults and parents are mostly used, and the Chinese translation version of CQLQ and LCQ is still the main method. There is still no cough specific quality of life measurement tool for children with chronic cough in China. Cc-qol, a specific scale for chronic cough in children, has not been promoted, and no relevant verification of the applicability, validity and reliability of the Chinese version has been found. Therefore, this study aims to verify and compare the applicability, reliability and validity of CC-QOL Chinese version in China through questionnaire survey and follow-up of children with chronic cough.


Description:

Descriptive Score: CC-QOL, CET,VAS, Peds-QOL,SCAS and Verbal category Score (VCD); descriptive score: DESCRIPTIVE score; descriptive score: DESCRIPTIVE score; descriptive score: DESCRIPTIVE score; To evaluate the reliability and validity of Cc-QOL in evaluating children's quality of life in China, Compare and analyze Leicester cough questionnaire(LCQ) and child chronic cough-specific quality of life measure Cc-qol was used to evaluate the quality of life in children with chronic cough.


Recruitment information / eligibility

Status Recruiting
Enrollment 180
Est. completion date May 5, 2026
Est. primary completion date December 30, 2024
Accepts healthy volunteers No
Gender All
Age group 7 Years to 14 Years
Eligibility Inclusion Criteria: - 1.Age 7-14; - 2.Disease duration > 4 weeks; - 3.Spontaneous cough as the main or only clinical symptom? Exclusion Criteria: - Chest X-ray was unremarkable, excluding cystic fibrosis, typical asthma or dyspnea, and other underlying diseases.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
The reliability and validity of the Chinese version of CC-QoL
Cc-qol, LCQ, and VCD were repeated 1-2 times before and 1-13 weeks after treatment.

Locations

Country Name City State
China Guangzhou institute of respiratory disease Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Guangzhou Institute of Respiratory Disease

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Validity Validity mainly evaluates the accuracy, validity and correctness of the scale, that is, the deviation between the measured value and the true target value.Validity is meant to reflect whether a measuring tool can effectively measure what it is intended to measure, that is, the extent to which the actual measured results agree with the expected results. At first visit, before medication, 2 weeks and 6 weeks after treatment initiation
Primary Reliability Reliability refers to the reliability, stability and consistency of the survey results, that is, accuracy.It is generally believed that reliability reflects the variation degree caused by measurement error or observation error, that is, random error.Common indicators:
Common indicators:
It is generally believed that Cronbach's alpha should be above 0.7. Retest reliability: the same questionnaire is used to measure the same group of respondents repeatedly at different times, and the consistency between the two results is retest reliability.
At first visit, before medication, 2 weeks and 6 weeks after treatment initiation
Secondary Sensitivity To evaluate the sensitivity of the questionnaire to measurements before and after treatment At first visit, before medication, 2 weeks and 6 weeks after treatment initiation
See also
  Status Clinical Trial Phase
Completed NCT01432730 - A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006) Phase 2
Not yet recruiting NCT01413698 - Cough Count Validation N/A
Completed NCT03639727 - Cough in Eastern and Central Finland N/A
Completed NCT03696108 - A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038) Phase 3
Recruiting NCT03638063 - ATP and Capsaicin Cough Provocation Test in Chronic Cough and Bronchiectasis
Recruiting NCT06376448 - An Observational Study Using Novel Questionnaire to Characterize Cough Phenotypes in Patients With Chronic Cough
Completed NCT03172130 - Sham CPAP vs. Straight CPAP for Chronic Cough N/A
Recruiting NCT06286163 - Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients
Completed NCT03622216 - A Dose Escalation Study of Bradanicline in Refractory Chronic Cough Phase 2
Recruiting NCT05522699 - Cough Suppressive Therapy in Patients With Chronic Cough N/A
Completed NCT01297790 - Cough Responses to Tussive Agents in Health and Disease N/A
Completed NCT04193202 - Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043) Phase 3
Completed NCT01865422 - French Linguistic and Metric Validations of Parent-proxy QOL Chronic Cough Specific Questionnaire (PC-QOL) N/A
Completed NCT04525885 - A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension Phase 3
Completed NCT04193176 - Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042) Phase 3
Recruiting NCT03787511 - Chronic Cough and Small Fiber Neuropathy N/A
Terminated NCT03864328 - A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF Phase 2
Completed NCT05274516 - A Trial of HRS-2261 in Healthy Subjects After Single and Multiple Oral Administration Phase 1
Not yet recruiting NCT01807832 - The Use of Capsaicin Challenge for Diagnosis, Monitoring and Follow-up of Chronic Cough. N/A
Enrolling by invitation NCT05689307 - Validation Study With a Non-CE Marked Medical Device (MD) N/A